| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(09)70142-1 |
| P698 | PubMed publication ID | 19482241 |
| P50 | author | David Cunningham | Q38803238 |
| P2093 | author name string | Ian Chau | |
| P2860 | cites work | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer | Q33384357 | ||
| Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation | Q36784813 | ||
| Management of bevacizumab-associated bowel perforation: a case series and review of the literature | Q37007540 | ||
| Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis | Q37501707 | ||
| Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. | Q46029883 | ||
| Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer | Q46892024 | ||
| Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer | Q46966648 | ||
| Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. | Q51776237 | ||
| Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening | Q80688840 | ||
| P433 | issue | 6 | |
| P921 | main subject | bevacizumab | Q413299 |
| P304 | page(s) | 534-536 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Bevacizumab-associated gastrointestinal perforation | |
| P478 | volume | 10 |
| Q57088820 | A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection |
| Q43550192 | Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. |
| Q38260176 | Bevacizumab: a review of its use in advanced cancer |
| Q37650308 | Palliative treatment of unresectable metastatic colorectal cancer |
| Q35680276 | Safety and efficacy of palliative colorectal stent placement using a nasal endoscope technique |
Search more.